Introduction Anadys Pharmaceuticals (Anadys) is a biopharmaceutical company, engaged in discovery, development, and commercialization of small molecule medicines for the treatment of viral diseases and cancer. The company strategically restructured its business and operations to stay focused on the development of proprietary ANA598 and ANA773; and to optimize the efficient use of its cash position. Scope - Contains corporate strategy, value chain presence and SWOT Analysis
- Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
- Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights The company’s pipeline portfolio consists of ANA598, a non-nucleoside NS5B polymerase inhibitor for the treatment of chronic HCV infection; and ANA773 a novel Toll-Like Receptor-7 (TLR-7) agonist oral prodrug being developed for the treatment of cancer. Both these product candidates are currently in preclinical development.The company recognizes revenues in the form of payments from its collaborators/licensors such as Novartis, Roche, etc. for compound licenses, technology access fees, option fees, research services, milestones and royalty obligations.The company’s total revenues increased at a CAGR of 43.4% during 2002-2006, from $1.3 million to $5.4 million. This represents an absolute total growth of +$4.1 million for total revenues. The company’s only contributor to revenue growth during 2002-2006 was licenses, collaboration and others. Reasons to Purchase - Access all the important information and analysis on the company in a single report
- Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to company’s adjusted five year financial data along with key ratios and market capitalization
TABLE OF CONTENTS Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 8
Company Financials 10
Stock Market Performance 10
P&L 12
Balance Sheet 15
Cash Flow 15
Products & Services 16
Pipeline Products 16
AC Forecast Product Sales 17
Competitors and Strategic Business Relationships 18
Key Competitors 18
Key Suppliers 19
Key Clients 20
Shareholding Structure 21
Strategy 22
Company View 22
Corporate Strategy 24
SWOT Analysis 25
Overview 25
Strengths 26
Weaknesses 27
Opportunities 28
Threats 29
Value Chain Analysis 30
Overview 30
Discovery and Product Development 30
Scorecard 31
Overview 31
Scorecard Analysis 32
Key Employees 33
List of Key Employees 33
Key Employee Biographies 34
Financial and Operational Overview 41
Financial and Operational Overview 41
APPENDIX 43
Ask the analyst 43
Datamonitor consulting 43
Disclaimer 43
TABLE OF FIGURES
Figure 1: Anadys - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
TABLE OF TABLES
Table 1: Anadys - Key Facts 6
Table 2: Anadys - Year-End Share Price and Market Capitalization, 2002-2006 ($) 10
Table 3: Anadys - Key Events Impacting Share Price Performance 11
Table 4: Anadys - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
Table 5: Anadys - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 14
Table 6: Anadys - Balance Sheet, 2002-2006 ($ Mn) 15
Table 7: Anadys - Cash Flow, 2002-2006 ($ Mn) 15
Table 8: Anadys - In-house Pipeline Products 16
Table 9: Anadys - Forecast Sales, 2006-2010 ($ Mn) 17
Table 10: Anadys - Key Competitors 18
Table 11: Anadys - Key Suppliers 19
Table 12: Anadys - Key Clients 20
Table 13: Anadys - Key Shareholders 21
Table 14: Anadys - SWOT Analysis Summary 25
Table 15: Anadys - Value Chain Analysis 30
Table 16: Anadys - Scorecard 31
Table 17: Anadys - Key Employees 33
Table 18: Anadys - Financial and Operational Overview 41
Pages: 43
|
